Healthcare Industry News: non-Hodgkin’s lymphoma
News Release - April 22, 2008
NCCN Updates Non-Hodgkin's Lymphoma GuidelinesFORT WASHINGTON, Pa.--(HSMN NewsFeed)--The National Comprehensive Cancer Network (NCCN) announces several new updates to the NCCN Clinical Practice Guidelines in Oncology™ non-Hodgkin’s lymphoma (NHL). These changes highlight leading developments in the treatment of NHL and represent the recognized standard for clinical care in oncology in both the community and the academic practice settings.
Bendamustine was recently approved by the FDA for the treatment of patients with CLL based on the results of a pivotal phase III study, which showed that bendamustine was more effective than chlorambucil in patients with untreated CLL. Results of this international phase III study were presented at the 2007 American Society of Hematology Annual Meeting. At a median follow-up of 18.5 months, bendamustine produced a significantly higher overall response rate (68% vs. 39% for chlorambucil with a complete response of 30% vs. 2% for chlorambucil), median progression-free survival (21.7 months vs. 9.3 months with chlorambucil) and median duration of remission (18.9 months vs. 6.1 months with chlorambucil).
Bendamustine with or without rituximab is also included as an option for second-line therapy for patients with follicular lymphoma (FL) and mantle cell lymphoma (MCL) with a category 2B designation. This recommendation is based on the available data suggesting well-documented activity for bendamustine in patients with FL and MCL.
About the National Comprehensive Cancer Network
The National Comprehensive Cancer Network (NCCN), a not-for-profit alliance of 21 of the world’s leading cancer centers, is dedicated to improving the quality and effectiveness of care provided to patients with cancer. Through the leadership and expertise of clinical professionals at NCCN Member Institutions, NCCN develops resources that present valuable information to the numerous stakeholders in the health care delivery system. As the arbiter of high-quality cancer care, NCCN promotes the importance of continuous quality improvement and recognizes the significance of creating clinical practice guidelines appropriate for use by patients, clinicians, and other health care decision-makers. The primary goal of all NCCN initiatives is to improve the quality, effectiveness, and efficiency of oncology practice so patients can live better lives.
For more information, visit www.nccn.org.
The NCCN Member Institutions are: City of Hope, Los Angeles, CA; Dana-Farber/Brigham and Women’s Cancer Center | Massachusetts General Hospital Cancer Center, Boston, MA; Duke Comprehensive Cancer Center, Durham, NC; Fox Chase Cancer Center, Philadelphia, PA; Huntsman Cancer Institute at the University of Utah, Salt Lake City, UT; Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance, Seattle, WA; Arthur G. James Cancer Hospital & Richard J. Solove Research Institute at The Ohio State University, Columbus, OH; The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD; Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL; Memorial Sloan-Kettering Cancer Center, New York, NY; H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL; Roswell Park Cancer Institute, Buffalo, NY; Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine, St. Louis, MO; St. Jude Children’s Research Hospital/University of Tennessee Cancer Institute, Memphis, TN; Stanford Comprehensive Cancer Center, Stanford, CA; University of Alabama at Birmingham Comprehensive Cancer Center, Birmingham, AL; UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA; University of Michigan Comprehensive Cancer Center, Ann Arbor, MI; UNMC Eppley Cancer Center at The Nebraska Medical Center, Omaha, NE; The University of Texas M. D. Anderson Cancer Center, Houston, TX; and Vanderbilt-Ingram Cancer Center, Nashville, TN.
Source: National Comprehensive Cancer Network
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.